[Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy].
Lists
Only you see this
Abstract
<b>Objectives:</b> To explore the incidence and factors of severe leukopenia and/or thrombocytopenia in newly diagnosed patients with chronic myeloid leukemia (CML) to probe their impacts on cytogenetic and molecular responses, progression free survival (PFS) and overall survival (OS) . <b>Methods:</b> Data of newly diagnosed patients with CML in the chronic phase (CP) and/or accelerated phase (AP) were retrospectively collected and analyzed. <b>Results:</b> 855 CML patients [including 744 (87%) in the CP and 111 (13.0%) in the AP] were included in this study. 523 (61.2%) patients were male with a median age of 39 years (range, 14-87 years) . 749 (87.6%) patients received imatinib, 93 (10.9%) nilotinib, and 13 (1.5%) dasatinib, respectively as front-line therapy. At a median treatment of 1 month (range, 0.1-7.0 months) , 137 (16.0%) developed ≥grade 3 leukopenia and/or thrombocytopenia and recovered 0.6 month (range, 0.3-6.5 months) . Multivariate analysis showed that female gender (<i>OR</i>=1.5, 95%<i>CI</i> 1.0-2.2, <i>P</i>=0.033) , WBC ≥100×10<sup>9</sup>/L (<i>OR</i>=1.9, 95%<i>CI</i> 1.3-2.8, <i>P</i>=0.001) , CP in Sokal high-risk (<i>OR</i>=2.2, 95%<i>CI</i> 1.2-3.9, <i>P</i>=0.005) , AP with ≥15% blast cells in blood or bone marrow (<i>OR</i>=5.1, 95%<i>CI</i> 1.9-13.3, <i>P</i>=0.001) were factors associated with higher incidence of ≥grade 3 leukopenia and/or thrombocytopenia. Severe leukopenia and/or thrombocytopenia with time of drug discontinuance >2 weeks was associated with lower probabilities of achieving complete cytogenetic (<i>OR</i>=0.4, 95%<i>CI</i> 0.3-0.6, <i>P</i><0.001) , severe leukopenia and/or thrombocytopenia, no matter the time of drug discontinuance >2 weeks or ≤2 weeks, were associated with lower probabilities of achieving major molecular responses (<i>OR</i>=0.3, 95%<i>CI</i> 0.2-0.5, <i>P</i><0.001; <i>OR</i>=0.7, 95%<i>CI</i> 0.5-1.0, <i>P</i>=0.036) and MR4.5 (<i>OR</i>=0.2, 95%<i>CI</i> 0.1-0.5, <i>P</i>=0.002; <i>OR</i>=0.7, 95%<i>CI</i> 0.4-1.1, <i>P</i>=0.110) ; however, those had no impacts on PFS and OS. <b>Conclusions:</b> Severe leukopenia and/or thrombocytopenia were common adverse events during TKI therapy. Female patients, WBC ≥100×10<sup>9</sup>/L at diagnosed, CP in Sokal high-risk, CML-AP with ≥15% blast cells in blood or bone marrow were at high risk for higher incidence of severe leukopenia and/or thrombocytopenia. Those severe adverse events had impacts on lower cytogenetic and molecular response.
BibTeX
@inproceedings{yu2019severe,
author = {Lu Yu and Y Z Qin and Yuni Lai and Hongxia Shi and Xiao‐Jun Huang and Qian Jiang},
title = {{[Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy].}},
booktitle = {PubMed},
year = {2019},
doi = {10.3760/cma.j.issn.0253-2727.2019.04.004},
}Loading related content...